ALI HEALTH (00241) surged over 5% again, bringing its cumulative stock price increase for the month to more than 30%. At the time of writing, the stock was up 4.89%, trading at HK$6.86 with a turnover of HK$613 million.
On the news front, a milestone solution from China has emerged in the global treatment of infantile hemangioma. The improved new drug Timolol Maleate Gel (brand name: Bemeijing®), independently developed over twelve years by Beijing Meiersen Pharmaceutical Technology Development Co., Ltd., has been exclusively launched on ALI HEALTH's platform.
Approved for market by the National Medical Products Administration on September 30, 2025, this drug is the world's first and currently only topical gel approved for treating "proliferative superficial infantile hemangioma," marking a critical leap for China from following to leading in this therapeutic area.
Notably, coinciding with Bemeijing®'s exclusive launch on ALI HEALTH, the product's value has received authoritative certification from the national drug price management system. On the morning of January 13, the China Drug Price Registration System simultaneously issued the first overseas version drug price certificate to Bemeijing®, establishing a traceable and referenceable price benchmark for China's original research drugs in the international market.
This mechanism fills a gap in the certification of Chinese commodity drug prices for international applications and provides more standardized, transparent, professional value support for China's innovative drugs in global cooperation, registration, and payment negotiations.
Comments